Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On October 17, 2024, we reported on a study presented at IDWeek 2024 that examined the association between social vulnerability, race, and influenza, COVID-19, and respiratory syncytial virus (RSV) vaccine uptake in the US.
The study
Researchers analyzed data from 341 029 patients who were diagnosed with acute respiratory infections at University Hospitals of Cleveland between October 2023 and April 2024. Patient demographics and vaccination statuses were collected from health records and matched with data from the US CDC’s Social Vulnerability Index (SVI). Researchers then geocoded and segmented the data into quartiles, with Q5 being the highest SVI category and Q1 being the lowest.
Among the cohort, 60% were women and 81% were White, according to investigators. Black individuals were overrepresented among individuals in SVI Q4 at 37% and underrepresented among the least vulnerable population (ie, Q1) at 3.2%, despite making up 14% of the study’s population.
The findings
Vaccine uptake among all participants regardless of SVI quartile and race was 37% for influenza, 14% for SARS-CoV-2, and 8.8% for RSV. Vaccination rates decreased, however, as the SVI quartile increased, particularly among Black participants.
After investigators adjusted for age, sex, and race, they found that the odds of receiving an influenza vaccine were lower for Black individuals compared to White individuals in all SVI quartiles, with the greatest disparity in SVI Q5 (Black: prevalence ratio [PR] 0.59, 95% CI 0.57-0.61; White: PR 0.72, 95% CI 0.70-0.75). Similarly, they also reported that the odds of receiving a SARS-CoV-2 vaccine and RSV vaccine were lower for Black individuals compared to White individuals across all SVI quartiles.
Authors' comment
"Even when controlling for demographic factors, household income, health insurance coverage and geographic location, the study’s findings maintain that neighborhood factors and race are significantly associated with vaccination status against common respiratory viruses. Disparities this vast are not to be overlooked — they require multifaceted interventions that meet people where they are socially and increase access to essential preventive measures.”
Click here for more details.
Social, Racial Disparities in Flu, COVID-19, RSV Vaccine Uptake: Daily Dose
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On October 17, 2024, we reported on a study presented at IDWeek 2024 that examined the association between social vulnerability, race, and influenza, COVID-19, and respiratory syncytial virus (RSV) vaccine uptake in the US.
The study
Researchers analyzed data from 341 029 patients who were diagnosed with acute respiratory infections at University Hospitals of Cleveland between October 2023 and April 2024. Patient demographics and vaccination statuses were collected from health records and matched with data from the US CDC’s Social Vulnerability Index (SVI). Researchers then geocoded and segmented the data into quartiles, with Q5 being the highest SVI category and Q1 being the lowest.
Among the cohort, 60% were women and 81% were White, according to investigators. Black individuals were overrepresented among individuals in SVI Q4 at 37% and underrepresented among the least vulnerable population (ie, Q1) at 3.2%, despite making up 14% of the study’s population.
The findings
Vaccine uptake among all participants regardless of SVI quartile and race was 37% for influenza, 14% for SARS-CoV-2, and 8.8% for RSV. Vaccination rates decreased, however, as the SVI quartile increased, particularly among Black participants.
After investigators adjusted for age, sex, and race, they found that the odds of receiving an influenza vaccine were lower for Black individuals compared to White individuals in all SVI quartiles, with the greatest disparity in SVI Q5 (Black: prevalence ratio [PR] 0.59, 95% CI 0.57-0.61; White: PR 0.72, 95% CI 0.70-0.75). Similarly, they also reported that the odds of receiving a SARS-CoV-2 vaccine and RSV vaccine were lower for Black individuals compared to White individuals across all SVI quartiles.
Authors' comment
"Even when controlling for demographic factors, household income, health insurance coverage and geographic location, the study’s findings maintain that neighborhood factors and race are significantly associated with vaccination status against common respiratory viruses. Disparities this vast are not to be overlooked — they require multifaceted interventions that meet people where they are socially and increase access to essential preventive measures.”
Click here for more details.
Untreated Depression, Anxiety Worsen COPD Outcomes: Daily Dose
Your daily dose of the clinical news you may have missed.
Primary Viewpoints: Immunizations with Dr Steven P. Furr
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.
Second Measles-Related Death in a Child Reported in Texas as US Cases Surpass 600
As the US measles outbreak tops 600 cases, Texas reported a second child's death in a young girl who was unvaccinated and had no underlying health conditions.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Depression, Anxiety Underrecognized and Undertreated in COPD, Increasing Disease Burden
A new analysis reveals significant gaps in diagnosis of and treatment for psychiatric disorders in adults with COPD and calls for larger, longitudinal studies.
Sanofi's Chlamydia Vaccine Granted FDA Fast Track Designation
The FDA granted fast track designation to Sanofi’s chlamydia vaccine candidate today, aiming to prevent infections and address an unmet public health need.
Untreated Depression, Anxiety Worsen COPD Outcomes: Daily Dose
Your daily dose of the clinical news you may have missed.
Primary Viewpoints: Immunizations with Dr Steven P. Furr
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.
Second Measles-Related Death in a Child Reported in Texas as US Cases Surpass 600
As the US measles outbreak tops 600 cases, Texas reported a second child's death in a young girl who was unvaccinated and had no underlying health conditions.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Depression, Anxiety Underrecognized and Undertreated in COPD, Increasing Disease Burden
A new analysis reveals significant gaps in diagnosis of and treatment for psychiatric disorders in adults with COPD and calls for larger, longitudinal studies.
Sanofi's Chlamydia Vaccine Granted FDA Fast Track Designation
The FDA granted fast track designation to Sanofi’s chlamydia vaccine candidate today, aiming to prevent infections and address an unmet public health need.